- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07942077
FLASH Biomarker Study
Biomarker Characterization in Patients Undergoing Ultra-High Dose Rate (ConformalFLASH®) on the C-FLASH-01 Trial
This is a single-center, non-interventional biospecimen collection protocol that accompanies C-FLASH-01 (Protocol IBA-04-UP, IDE G260113), a pilot trial of ultra-high dose rate proton reirradiation (ConformalFLASH) for head and neck cancer. Blood and saliva will be collected from up to 10 participants enrolled on the C-FLASH-01 trial at three time points: 1) within 4 weeks before the start of radiotherapy, 2) within 3 days of the last day of radiotherapy, and 3) within 4 months after completion of radiotherapy.
Visão geral do estudo
Status
Condições
Descrição detalhada
The study team hypothesize that biomarkers measurable in blood and saliva, including but not limited to cell-free DNA and cytokines, change over the course of ConformalFLASH reirradiation and are associated with normal tissue response/toxicity. This protocol does not include a study intervention; all radiotherapy is delivered under the separately approved parent protocol (Protocol IBA-04-UP, IDE G260113).
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Ching Lai
- Número de telefone: 267-250-9244
- E-mail: Ching.Lai@pennmedicine.upenn.edu
Estude backup de contato
- Nome: Karen Tang
- Número de telefone: 267-299-9618
- E-mail: Karen.Tang1@Pennmedicine.upenn.edu
Locais de estudo
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Perelman Center for Advanced Medicine, Department of Radiation Oncology
-
Contato:
- Ching Lai
- Número de telefone: 267-250-9244
- E-mail: Ching.Lai@pennmedicine.upenn.edu
-
Contato:
- Karen Tang
- Número de telefone: 267-299-9618
- E-mail: Karen.Tang1@Pennmedicine.upenn.edu
-
Investigador principal:
- Shervin Tabrizi, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Participants are recruited exclusively from among individuals enrolled on C-FLASH-01 (Protocol IBA-04-UP, IDE G260113) in the Department of Radiation Oncology at the University of Pennsylvania. No advertising, flyers, social media, or other external recruitment will be used, and no additional screening of the general population is required.
Descrição
Inclusion Criteria:
- Enrolled on C-FLASH-01 (Protocol IBA-04-UP, IDE G260113) and planned to receive ConformalFLASH reirradiation
- Male or female, aged 18 years or older
- Provision of signed and dated informed consent for this biospecimen protocol
- Stated willingness to comply with the specimen collection
Exclusion Criteria:
- Any condition that, in the judgment of the investigator, makes repeated peripheral venipuncture unsafe or infeasible
- Inability to provide informed consent
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: OTHER
- Perspectivas de Tempo: PROSPECTIVE
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Batched analysis of Biomarker dynamics in blood Including but not limited to cell-free DNA and cytokines, following ConformalFLASH reirradiation for up to 10 participants.
Prazo: - Collect blood (16 mL) between baseline (Screening, Enrollment, and Baseline) - (Visit 1) - Collect Blood (16 mL) end of Radiotherapy (Visit 2) - Collect Blood (16 mL) within 4 months after completion of radiotherapy (Post-Radiotherapy) - (Visit 3)
|
Change in biomarker measures (e.g., cell-free DNA and cytokines) in plasma between baseline, end of radiotherapy, and within 4 months after completion of radiotherapy. At each time point, 16 mL of peripheral blood will be drawn by a trained phlebotomist or delegated study team member into Streck Cell-Free DNA BCT tubes and EDTA tubes. The maximum cumulative volume drawn under this protocol is 48 mL per participant. Streck tubes stabilize cell-free DNA for the cell-free DNA analyses; EDTA tubes provide plasma and buffy coat for cytokine analyses and potential cellular analyses. At every collection - blood will be centrifuged; plasma and buffy coat aliquoted and stored at - 80 °C. |
- Collect blood (16 mL) between baseline (Screening, Enrollment, and Baseline) - (Visit 1) - Collect Blood (16 mL) end of Radiotherapy (Visit 2) - Collect Blood (16 mL) within 4 months after completion of radiotherapy (Post-Radiotherapy) - (Visit 3)
|
|
Batched analysis of Biomarker dynamic in the saliva including but not limited to cell-free DNA and cytokines, following ConformalFLASH reirradiation for up to 10 participants.
Prazo: - Between baseline (Screening, Enrollment, and Baseline Collection) - (Visit 1) - End of Radiotherapy Collection (Visit 2) - Within 4 months after completion of radiotherapy (Post-Radiotherapy Collection) - (Visit 3)
|
Change in biomarker measures (e.g., cell-free DNA and cytokines) in saliva between baseline, end of radiotherapy, and within 4 months after completion of radiotherapy. At each time point, saliva will be collected into a commercial saliva collection tube in accordance with the manufacturer's instructions, after the 30-minute interval. At every collection - Saliva will be stored at - 80 °C. |
- Between baseline (Screening, Enrollment, and Baseline Collection) - (Visit 1) - End of Radiotherapy Collection (Visit 2) - Within 4 months after completion of radiotherapy (Post-Radiotherapy Collection) - (Visit 3)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Shervin Tabrizi, MD, University of Pennsylvania
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- UPCC 16326
- 26-8473 (Outro identificador: University of Pennsylvania, Internal Review Broad (IRB))
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .